Agents shown to be effective in the prevention of osteoporotic fracture in postmenopausal women. There are no studies assessing antifracture efficiacy of interventions in chronic liver disease
| Spine | Non-vertebral | Hip | |
|---|---|---|---|
| HRT, hormone replacement therapy; NA, not assessed; ND, not demonstrated; * data inconsistent. | |||
| Grade A, meta-analysis or randomised controlled trial or at least one randomised controlled trial. | |||
| Grade B, from at least one well designed controlled study without randomisation, from at least one other well designed quasi-experimental study, or from well designed non-experimental descriptive studies, for example, comparative studies, correlation studies, case controlled studies. | |||
| Grade C, from expert committee reports/opinions/or clinical experience of authorities. | |||
| The tables come from the Royal College of Physician/Bone and Tooth Society updated guidelines on the “Management of osteoporosis”. | |||
| Alendronate | A | A | A |
| Calcitonin | A* | B | B |
| Calcitriol | A* | A* | NA |
| Calcium | A | B | B |
| Calcium and vitamin D | NA | A | A |
| Cyclical etidronate | A | B | B |
| HRT | A | A | B |
| Raloxifene | A | ND | ND |
| Risedronate | A | A | A |
| Vitamin D | NA | B | B |